Peracchia A, Ruol A, Narne S, Tiso E, Segalin A, Lazzaro S, Anselmino M, Bardini R
Istituto di Clinica Chirurgica I dell'Università di Padova.
Acta Otorhinolaryngol Ital. 1990 May-Jun;10(3):275-85.
66 consecutive patients with a tumor confined to the cervical esophagus underwent surgical resection. The comparison between clinical and pathological TNM stage showed a clinical understaging in 30 patients. 25 of the 56 patients who had undergone curative resection had lymph node metastases: positive mediastinal and abdominal nodes were found in 8 (32%) and 0 cases, respectively. The mean survival after curative resection of the 10 evaluable patients with metastatic periesophageal, recurrent and/or paratracheal nodes was 22.4 months; of the 6 evaluable patients with positive mediastinal nodes it was 10.3 months; and of the 5 patients with positive deep latero-cervical nodes it was 5.8 months. The 2-year actuarial survival after curative resection (in the 53 operative survivors) was as follows (according to pathologic TNM staging): Stage I (n = 3) 100%, Stage IIA (n = 17) 30%, Stage IIB (n = 3) 33%, and Stage III (n = 30) 22%. The exact location of neoplastic recurrence after curative resection was documented in 13 cases; it was in the neck in 8 cases (61%); both neck and at a distance in 3 cases (23%) and only at a distance in 2 (16%). The clinical TNM staging of cervical esophageal cancer was not in agreement with the pathological findings in nearly 50% of the cases and is, therefore, inaccurate and unreliable both for therapeutic decision-making and for prognostic evaluations. Endoscopic ultrasound, which was not used in most of the patients studied here, may improve the accuracy of clinical TNM staging. The N classification, which defines only the cervical nodes as regional nodes, appears to be arbitrary since the pathological staging showed metastatic mediastinal nodes in 32% of the N + cases, with a survival comparable to that of patients with metastatic nodes only in the neck. The prognostic value of pathological TNM staging was not confirmed in the present study since only Stage I patients had a significantly better prognosis than patients in the other stages. This may be due to the small number of patients considered or to lymph node understaging caused by the fact that most patients did not undergo mediastinal lymphadenectomy through a thoracotomy or a sternum splitting.
66例肿瘤局限于颈段食管的患者接受了手术切除。临床TNM分期与病理TNM分期比较显示,30例患者存在临床分期过低的情况。56例接受根治性切除的患者中,25例有淋巴结转移:分别有8例(32%)和0例发现纵隔和腹部淋巴结阳性。10例可评估的食管周围、复发和/或气管旁淋巴结转移患者根治性切除后的平均生存期为22.4个月;6例纵隔淋巴结阳性的可评估患者为10.3个月;5例颈深侧方淋巴结阳性患者为5.8个月。根治性切除后(53例手术幸存者)的2年精算生存率如下(根据病理TNM分期):Ⅰ期(n = 3)100%,ⅡA期(n = 17)30%,ⅡB期(n = 3)33%,Ⅲ期(n = 30)22%。13例记录了根治性切除后肿瘤复发的确切位置;8例(61%)位于颈部;3例(23%)颈部及远处均有复发;2例(16%)仅远处复发。近50%的颈段食管癌患者临床TNM分期与病理结果不一致,因此,其对于治疗决策和预后评估而言既不准确也不可靠。内镜超声在本研究的大多数患者中未使用,可能会提高临床TNM分期的准确性。N分期仅将颈部淋巴结定义为区域淋巴结,这似乎有些武断,因为病理分期显示32%的N+病例存在纵隔淋巴结转移,其生存率与仅颈部有转移淋巴结的患者相当。本研究未证实病理TNM分期的预后价值,因为只有Ⅰ期患者的预后明显优于其他期患者。这可能是由于纳入的患者数量较少,或者是由于大多数患者未通过开胸或胸骨劈开进行纵隔淋巴结清扫导致淋巴结分期过低。